- Home
- NGS vs RIGL Comparison
NGS vs RIGL Comparison
Compare NGS & RIGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NGS
- RIGL
- Stock Information
- Founded
- NGS 1998
- RIGL 1996
- Country
- NGS United States
- RIGL United States
- Employees
- NGS N/A
- RIGL N/A
- Industry
- NGS Oilfield Services/Equipment
- RIGL Biotechnology: Pharmaceutical Preparations
- Sector
- NGS Energy
- RIGL Health Care
- Exchange
- NGS Nasdaq
- RIGL Nasdaq
- Market Cap
- NGS 241.7M
- RIGL 486.4M
- IPO Year
- NGS 2002
- RIGL 2000
- Fundamental
- Price
- NGS $24.72
- RIGL $17.09
- Analyst Decision
- NGS Strong Buy
- RIGL Buy
- Analyst Count
- NGS 2
- RIGL 5
- Target Price
- NGS $26.50
- RIGL $34.80
- AVG Volume (30 Days)
- NGS 71.1K
- RIGL 203.8K
- Earning Date
- NGS 11-14-2024
- RIGL 11-07-2024
- Dividend Yield
- NGS N/A
- RIGL N/A
- EPS Growth
- NGS 605.21
- RIGL N/A
- EPS
- NGS 1.28
- RIGL 0.22
- Revenue
- NGS $152,305,000.00
- RIGL $157,374,000.00
- Revenue This Year
- NGS $30.81
- RIGL $48.98
- Revenue Next Year
- NGS $13.48
- RIGL $14.43
- P/E Ratio
- NGS $19.30
- RIGL $77.18
- Revenue Growth
- NGS 41.72
- RIGL 21.65
- 52 Week Low
- NGS $13.70
- RIGL $7.48
- 52 Week High
- NGS $28.50
- RIGL $29.82
- Technical
- Relative Strength Index (RSI)
- NGS 45.69
- RIGL 30.82
- Support Level
- NGS $23.70
- RIGL $16.68
- Resistance Level
- NGS $26.08
- RIGL $19.80
- Average True Range (ATR)
- NGS 1.16
- RIGL 1.53
- MACD
- NGS -0.49
- RIGL -1.05
- Stochastic Oscillator
- NGS 22.42
- RIGL 3.66
About NGS Natural Gas Services Group Inc.
Natural Gas Services Group Inc provides natural gas compression equipment and services to the energy industry. The company manufactures, fabricates, rents, sells, and maintains natural gas compressors and flare systems for oil and natural gas production and plant facilities. Its operating units include Rental, Sales, and Aftermarket services. The company generates the majority of its revenue by renting out low- to medium-horsepower compression equipment to natural gas production companies in unconventional oil and gas regions of the United States.
About RIGL Rigel Pharmaceuticals Inc.
Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's lead drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, the only oral spleen tyrosine kinase (SYK) inhibitor, Fostamatinib, R289, R552, R835, DS-3032, THF-beta Inhibitors, and AZD0449- Inhaled JAK Inhibitor.